The estimated Net Worth of Wendy S. Johnson is at least 3.03 千$ dollars as of 3 September 2021. Ms. Johnson owns over 1,000 units of Exagen Inc stock worth over 3,030$ and over the last 7 years she sold XGN stock worth over 0$. In addition, she makes 0$ as Independent Director at Exagen Inc.
Wendy has made over 1 trades of the Exagen Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she bought 1,000 units of XGN stock worth 14,020$ on 3 September 2021.
The largest trade she's ever made was buying 1,000 units of Exagen Inc stock on 3 September 2021 worth over 14,020$. On average, Wendy trades about 167 units every 0 days since 2017. As of 3 September 2021 she still owns at least 1,000 units of Exagen Inc stock.
You can see the complete history of Ms. Johnson stock trades at the bottom of the page.
Wendy Johnson has been appointed as Independent Director of the Company effective 10/1/2020. Ms. Johnson has a distinguished career in healthcare performing various roles integral to corporate growth. She is currently the Chief Operating Officer of Reneo Pharmaceuticals where she is responsible for day-to-day operations, and was instrumental in setting up the company's UK corporate entity. Ms. Johnson was previously the Interim Chief Operating Officer of AmpliPhi Biosciences Corporation from September 2014 to January 2017, and a member of its board of directors from May 2014 until its merger with C3J Therapeutics (Armata Pharmaceuticals) in May 2019. From 2005 to January 2014, Ms. Johnson served as a venture partner at ProQuest Investments, a venture capital firm. From 2006 to January 2014, Ms. Johnson served as the President and Chief Executive Officer of Aires Pharmaceuticals, a ProQuest portfolio company, until its sale to MAST Therapeutics in 2014. Prior to joining ProQuest, she held senior business and corporate development positions at Salmedix Inc., WomenFirst Healthcare, Prizm Pharmaceuticals (Selective Genetics Inc.), Cytel Corp., Synbiotics Corp., and Murex Corp. (Cambridge U.K.). Additionally, Ms. Johnson served as Assistant Director with the Center for Devices and Radiological Health at the U.S. Food and Drug Administration. Ms. Johnson is also presently on the Board of Directors of MorphoSys AG, one of the oldest biotechnology companies in Europe. Ms. Johnson received an M.B.A. from Loyola University Maryland, her M.S. in Clinical Microbiology from the Hahnemann Medical School, and her B.S. in Microbiology from the University of Maryland.
Wendy's mailing address filed with the SEC is C/O EXAGEN INC., 1261 LIBERTY WAY, VISTA, CA, 92081.
Over the last 5 years, insiders at Exagen Inc have traded over 8,628,989$ worth of Exagen Inc stock and bought 556,568 units worth 6,283,309$ . The most active insiders traders include James L L Tullis、Bio Exagen, L.P.H.I.G. Gpii...、Jeffrey Thomas Elliott. On average, Exagen Inc executives and independent directors trade stock every 48 days with the average trade being worth of 109,189$. The most recent stock trade was executed by John Aballi on 16 May 2024, trading 40,401 units of XGN stock currently worth 77,570$.
exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.
Exagen Inc executives and other stock owners filed with the SEC include: